Bonnie W. Nannenga-Combs, Ph.D. is a director in Sterne Kessler’s Biotechnology & Chemical PracticeGroup and a co-chair of the Patent Prosecution Practice. Bonnie represents clients in various stages ofdevelopment and commercialization of life science therapeutics, such as gene therapy, RNA therapies,antisense technologies, biologics, therapeutic antibodies, cell therapy, vaccines, diagnostics, small andlarge molecule formulations, and nucleic acid delivery. She counsels domestic and international clientson patent procurement, clearance strategies, and management of complex worldwide patent portfolios.Bonnie’s expertise includes developing exclusivity strategies for companies with therapies targetinggenetic diseases, including orphan and rare diseases, and vaccines for bacterial and viral diseases.
Bonnie counsels clients during IP due diligence for asset acquisition and M&A. She is particularly skilledin identifying portfolio strengths and weaknesses, which helps clients assess IP portfolio valuation andrisk management. Bonnie excels at building relationships with clients to better understand each client’sunique IP needs, which is critical in assisting clients to achieve their business goals such as executingstrategic partnerships and M&A transactions, IP portfolio building, IP risk management, raising funds,and going public.
Bonnie is active in the firm’s Pro Bono Practice. She works with pro bono clients to prepare andprosecute patents that can be used to help advance economic, social, and cultural rights. Bonnie earned her Ph.D. in molecular & cellular biology at Baylor College of Medicine. She received herJ.D. from Seattle University School of Law and a B.S. in biology from Hope College.